Information Provided By: 
Fly News Breaks for September 6, 2017
PX, MNK
Sep 6, 2017 | 07:39 EDT
As previously reported, Morgan Stanley analyst David Risinger downgraded Mallinckrodt to Equal Weight from Overweight as he believes yesterday's unfavorable district court ruling in Mallinckrodt's (MNK) suit against Praxair (PX) has increased the risk of an Inomax generic potentially as soon as October 2018, compared to his prior expectation of 2031. The analyst, who thinks heightened Acthar concentration and Generics segment pressures limit the stock's upside potential, lowered his price target on Mallinckrodt shares to $40 from $65.
News For MNK;PX From the Last 2 Days
